Significant Improvement in PFS Noted With Second-Line Nivolumab Plus Ipilimumab in Advanced Melanoma

Source: Cancer Network,  April 2022

Patients with advanced melanoma receiving nivolumab plus ipilimumab in the second-line setting had significant improvement in progression-free survival.

The phase 2 SWOG S1616 trial (NCT03033576) revealed that patients with stage III unresectable or stage IV melanoma that had been previously treated and were administered nivolumab (Opdivo) plus ipilimumab (Yervoy) in the second-line setting experienced significantly improved progression-free survival vs ipilimumab alone, according to results presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

At a median follow-up of 28.3 months, the median PFS was 3.0 months (90% CI, 2.8-5.3) with the combination vs 2.7 months (90% CI, 2.5-2.9) with ipilimumab alone (HR, 0.63; 90% CI, 0.41-0.97; P = .037). The estimated 6-month PFS rates were 34% (90% CI, 25%-44%) and 13% (90% CI, 4%-27%), respectively.